Paya C V, Fung J J, Nalesnik M A, Kieff E, Green M, Gores G, Habermann T M, Wiesner P H, Swinnen J L, Woodle E S, Bromberg J S
Department of Immunology, Mayo Transplant Center, Mayo Clinic, Rochester, Minnesota 55905, USA.
Transplantation. 1999 Nov 27;68(10):1517-25. doi: 10.1097/00007890-199911270-00015.
Epstein-Barr virus-induced posttransplant lymphoproliferative disease (EBV-PTLD) continues to be a major complication after solid organ transplantation in high-risk patients. Despite the identification of risk factors that predispose patients to develop EBV-PTLD, limitations in our knowledge of its pathogenesis, variable criteria for establishing the diagnosis, and lack of randomized studies addressing the prevention and treatment of EBV-PTLD hamper the optimal management of this transplant complication. This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, and provides recommendations for future areas of study.
爱泼斯坦-巴尔病毒(EBV)诱导的移植后淋巴细胞增生性疾病(EBV-PTLD)仍然是高危患者实体器官移植后的主要并发症。尽管已确定了使患者易患EBV-PTLD的危险因素,但我们对其发病机制的认识存在局限性、诊断标准不一,且缺乏针对EBV-PTLD预防和治疗的随机研究,这些都妨碍了对这种移植并发症的最佳管理。本综述总结了关于EBV-PTLD的现有知识,并基于两次关于该主题的国际会议,提出了未来研究领域的建议。